News

GlobalData on MSN17h
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.
Zacks Investment Research on MSN19h
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...
Zacks.com on MSN23h
Biogen Inc. (BIIB) Q1 Earnings Lag Estimates
Biogen (BIIB) delivered earnings and revenue surprises of -7.36% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?